Eisai Racks Up 5.9% Sales Increase in April-September on Lenvima Growth, Despite Price Cuts, COVID-19

Eisai’s group sales rose 5.9% in the first half of FY2020, propped up by the robust performance of its anticancer agent Lenvima (lenvatinib), despite the negative factors such as drug price revisions and the COVID-19 pandemic, according to its earnings...read more